Back

Investigation for yellow fever virus exposure in humans from central/south-eastern Anatolia

Abstract number: P1407

Ergunay K., Saygan M., Aydogan S., Litzba N., Niedrig M., Ozer N., Bulut S., Us D.

Objectives: Yellow fever is a viral hemorrhagic fever with high mortality that is transmitted by mosquitoes. The disease is present now in Africa and Central/South America, although historically, large outbreaks occurred in Europe and North America. Mosquitoes capable of transmitting yellow fever exist in regions where the disease does not presently occur. Data available on possible Yellow Fever virus (YFV) activity in Turkey is limited to a single study where total YFV antibodies were found in 9.7% in a survey of 1074 sera from Aegean region of Turkey but none could be confirmed. The aim of this study, partially supported by Hacettepe University Research Fund and Turkish Red Crescent Society, was to investigate YFV exposure in persons from Central and Southeast Anatolia. This is the first study to investigate YFV exposure in these regions.

Methods: A total of 1523 sera, that comprise 1454 sera from blood donors at 4 major branches (Ankara, Konya, Eski[scedil]ehir and Zonguldak) of Turkish Red Crescent Middle Anatolia Regional Blood Center, along with 69 sera obtained from adults attending to outpatient clinics of State Medical Centers of Sanliurfa and Siverek (southeastern Turkey) for other laboratory analyses were included after informed consent. All individuals were asked to fill out a survey to reveal risk factors for vector-borne viral infections and persons with a history of Yellow Fever vaccination were excluded. All sera were previously evaluated with commercial ELISA assays for other flaviviruses (Anti-Dengue virus, Anti-TBE virus and Anti-West Nile virus ELISA, EUROIMMUN, Germany) and found to be negative. Evaluation for the presence of YFV IgG was performed by a commercial IgG indirect immunofluorescence test (IIFT) (Anti-Yellow Fever virus IgG IIFT, EUROIMMUN, Germany). All positive samples were retested twice and further evaluated by YFV plaque reduction neutralization assay to confirm antibody specificity.

Results: A total of 10 sera (10/1523, 0.65%) were positive in initial evaluation and repeat testing by the YFV IgG IIFT. All were negative in the plaque reduction neutralization assay.

Conclusions: No confirmed exposure to YFV could be demonstrated in this study. In order to rule out the presence of YFV activity in Anatolia, detailed vector surveillence data should be collected and thoroughly evaluted to identify mosquito species that may act as potential vectors.

Session Details

Date: 10/04/2010
Time: 00:00-00:00
Session name: Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases
Subject:
Location: Vienna, Austria, 10 - 13 April 2010
Presentation type:
Back to top